Holen Sie sich die Stockscreener-App
14.77
4.59%
-0.71
Handel nachbörslich:
14.50
-0.27
-1.83%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$15.48
Offen:
$15.16
24-Stunden-Volumen:
3.36M
Relative Volume:
1.52
Marktkapitalisierung:
$1.01B
Einnahmen:
$1.01B
Nettoeinkommen (Verlust:
$-204.71M
KGV:
-4.8125
EPS:
-3.0691
Netto-Cashflow:
$-29.67M
1W Leistung:
-25.67%
1M Leistung:
-22.99%
6M Leistung:
-15.70%
1J Leistung:
-35.73%
1-Tages-Spanne:
$14.18
$15.35
1-Wochen-Bereich:
$14.18
$20.03
52-Wochen-Spanne:
$9.98
$29.65
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
14.77 | 1.06B | 1.01B | -204.71M | -29.67M | -3.0691 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Hochstufung | Truist | Hold → Buy |
| 2026-03-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-23 | Hochstufung | Lake Street | Hold → Buy |
| 2026-02-20 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-01-27 | Fortgesetzt | TD Cowen | Buy |
| 2025-12-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | Fortgesetzt | Stifel | Hold |
| 2025-09-08 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
TNDM Q1 Deep Dive: Margin Expansion and Pipeline Advances Amid Business Model Shift - Yahoo! Finance Canada
Tandem Diabetes Care, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:TNDM) 2026-05-11 - Seeking Alpha
Earnings call transcript: Tandem Diabetes Care Q1 2026 sees record sales, stock drops - Investing.com Canada
Truist Financial Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $31 - Moomoo
TNDM Maintained by Barclays -- Price Target Lowered to $55.00 - GuruFocus
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $24 to $50 - Moomoo
Compared to estimates, Tandem Diabetes Care (TNDM) Q1 earnings: A look at key metrics - MSN
Tandem Diabetes Care (TNDM) Nears Break Even In Q4 Losses Challenging Bearish Narratives - Sahm
Tandem Diabetes Care Q1 Earnings Call Highlights - TradingView
Why Tandem Diabetes (TNDM) Shares Are Trading Lower Today - TradingView
Tandem to file tubeless insulin pump with FDA this quarter - MedTech Dive
Mizuho Securities Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Raises Target Price to $24 - Moomoo
Tandem Diabetes Q1 2026 slides: record revenue, profitability returns By Investing.com - Investing.com Australia
TNDM Maintains Financial Forecast for 2026 with Sales Projections - GuruFocus
TNDM Reports Strong Q1 Revenue Growth - GuruFocus
Tandem Diabetes Care Announces First Quarter 2026 Financial Results - BioSpace
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
MSN Money - MSN
Tandem Diabetes Q1 2026 slides: record revenue, profitability returns - Investing.com India
Earnings call transcript: Tandem Diabetes Care Q1 2026 beats EPS forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Tandem Diabetes Care Q1 2026 beats EPS forecast - Investing.com
Tandem Diabetes Care, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Tandem Diabetes Care Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Tandem Diabetes Care (NASDAQ:TNDM) Surges 10% After Q1 Beat on Revenue and Earnings - ChartMill
Tandem Diabetes Care : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Compared to Estimates, Tandem Diabetes Care (TNDM) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
TNDM Financials: Income Statement, Balance Sheet & Cash Flow | Tandem Diabetes - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Tandem Diabetes Care (TNDM) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Earnings Flash (TNDM) Tandem Diabetes Care, Inc. Reports Q1 Revenue $247.2M, vs. FactSet Est of $240.4M - marketscreener.com
Q1 2026 Tandem Diabetes Care Inc Earnings Call Transcript - GuruFocus
Tandem Diabetes (NASDAQ: TNDM) lifts Q1 2026 margin as loss shrinks sharply - Stock Titan
Tandem Diabetes’s (NASDAQ:TNDM) Q1 CY2026: Beats On Revenue, Stock Jumps 10.9% - Yahoo Finance
Tandem Diabetes Care, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Tandem Diabetes shipped 29,000 insulin pumps and kept 2026 targets - Stock Titan
Tandem Diabetes (NASDAQ: TNDM) lifts Q1 2026 margins and reaffirms outlook - Stock Titan
Tandem Diabetes faces earnings test as pay-as-you-go shift weighs By Investing.com - Investing.com Australia
Tandem Diabetes faces earnings test as pay-as-you-go shift weighs - Investing.com Australia
A Look At Tandem Diabetes Care (TNDM) Valuation After FDA Clearance For Pregnancy Use Of Control IQ Plus - Sahm
Tandem Diabetes (TNDM) Q1 Earnings: What To Expect - The Globe and Mail
Tandem Diabetes Care upgraded by Robert W. Baird with a new price target - Quantisnow
Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032 - Quantisnow
Is FDA Pregnancy Clearance For Control-IQ+ Reshaping The Investment Case For Tandem Diabetes Care (TNDM)? - Sahm
Voya Financial (NYSE: VOYA) discloses 6.3% stake in Tandem Diabetes Care (TNDM) - Stock Titan
FDA Approves Automated Insulin Delivery System for Pregnancy in Type 1 Diabetes - Medical Dialogues
Price-Driven Insight from (TNDM) for Rule-Based Strategy - Stock Traders Daily
How Investors Are Reacting To Tandem Diabetes Care (TNDM) Expanding Control-IQ+ Use To Type 1 Pregnancies - Yahoo Finance
FDA flags high-risk recall for Tandem Diabetes Mobi pumps - MSN
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):